Tripos®, a leading provider of drug discovery informatics products and services, today announced that Agios Pharmaceuticals, Inc. has selected D360 as its enterprise solution for data integration, visualization, mining and analysis, after a year-long, multi-vendor competitive process.

In making the announcement, Tripos’ Chief Executive Officer, Jim Hopkins, said, “We are thrilled with Agios’ decision to adopt D360 and roll it out to their entire organization, from the individual bench scientist to the Chief Scientific Officer.” He added, “D360 has proven that it meets the performance and scalability requirements necessary to be deployed at the largest pharmaceutical organizations, and yet it is affordable and flexible enough to address the needs of life science research organizations of all sizes. The low ongoing maintenance overhead makes D360 the most cost effective solution on the market for any size life science organization, from Agios to Pfizer.”

D360 is used by scientists to integrate and provide robust access to multiple types of data, regardless of where it resides, including chemical, biological, PK/PD data and more. For example, D360’s integration with IDBS’s ActivityBase allows rapid and straightforward deployment, providing scientists throughout the organization with easy access to this valuable data.

“Many pharma and biotech research teams are now looking for improved data integration, mining and analysis solutions, and we are very pleased that Agios has been added to the growing family of D360 customers,” said James Hayden, Senior Vice President of Sales and Marketing for Tripos. “By integrating D360 with ActivityBase, we have reduced 50 or more mouse clicks down to one, making the large amount of chemical and biological data that is generated on a daily basis more available to the scientists that require it. This is crucial for alleviating the bottlenecks in data distribution to key decision makers and will allow companies to make pivotal decisions much faster.”

More information about D360’s data integration, mining, visualization and analysis capabilities can be found by contacting Tripos or visiting www.tripos.com/discovery360.

About Tripos

Tripos, a Certara™ Company, is a global leader in innovative scientific solutions enabling life science researchers to improve the efficiency of molecular discovery. Established in 1979, Tripos was the first company to bring scientific computational drug discovery capabilities to the pharmaceutical, chemical, food and fragrance industries, and today helps a broad range of companies and research facilities accelerate the identification and optimization of new compounds intended to become tomorrow’s drugs, foods, flavorings and fragrances.

About Certara

Certara is dedicated to improving human health through a broad spectrum of products and services, from molecular discovery to clinical research. Formed in 2008, Certara unites Tripos (www.tripos.com) and Pharsight Corporation (www.pharsight.com). Certara reduces the barriers between phases of research to speed discoveries in chemistry, and enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products.